Neoadjuvant combo efficacious in high-risk prostate cancer

"In our sample, nearly 10% of patients [with prostate cancer] had a gene variant that made them eligible for effective new therapies, with faster results than traditional referral for genetic testing and counseling,” said Maria I. Carlo, MD.

Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.

The deep learning software also showed no difference in the consistency of scoring with the Prostate Imaging-Reporting and Data System (PI-RADS).

Laura Bukavina, MD, and Kyle Rose, MD, discuss some of the notable abstracts from the 2023 ASCO GU conference.

Prostate cancer, bladder cancer, renal cell carcinoma were among the multitude of tumor types assessed in the analysis supporting the approval.

"The improvement in technologies could potentially assist radiation oncologists in making timely decisions,” said Himanshu Arora, PhD.